ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors ...Middle East

Partnership combines ARTBIO's AlphaDirect™ platform for 212Pb-based alpha radioligand therapies with 3B Pharmaceuticals' expertise in peptide radioligand therapy discovery and development ARTBIO gains exclusive global license for highly novel program close to clinical development...

Hence then, the article about artbio to enter into licensing and research partnership with 3b pharmaceuticals to advance a first in class alpha radioligand therapy for solid tumors was published today ( Thursday 14/11/2024 - 10:04 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ARTBIO to Enter into Licensing and Research Partnership with 3B Pharmaceuticals to Advance a First-in-Class Alpha Radioligand Therapy for Solid Tumors )

Also on site :

• President Trump Buys DraftKings, Red Rock, Sells Other Gaming Stocks
• Nordstrom Rack Has 'Stylish and 'Supportive' Sandals That You'll Want to Wear 'All Day' on Sale for 50% Off
• Walmart Is Selling a 'Wonderful' Marc Jacobs Tote Bag for $74 Off, and It's the Perfect 'Roomy' Travel Bag